Engineered immune cells take on Hard-to-Treat liver cancer

NCT ID NCT06084884

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tests a new treatment called AZD5851 for adults with advanced or recurrent liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are to check the treatment's safety and find the right dose, while also seeing if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    San Francisco, California, 94143, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Jacksonville, Florida, 32224, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Westwood, Kansas, 66205, United States

  • Research Site

    Rochester, Minnesota, 55905, United States

  • Research Site

    Hackensack, New Jersey, 07601, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15237, United States

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Osakasayama-shi, 589-8511, Japan

  • Research Site

    Seoul, 03080, South Korea

Conditions

Explore the condition pages connected to this study.